Completed PHASE1 INTERVENTIONAL 2-arm NCT02218346

Food Effect Study of AG-221 in Healthy Male Subjects

A Phase 1, Two-Way Crossover Study to Assess the Pharmacokinetics and Safety of a Single Dose of AG-221 in Healthy Male Subjects When Administered Under Fed and Fasted Conditions

Sponsor: Agios Pharmaceuticals, Inc.

Conditions Healthy Volunteers

Interventions AG221

Updated 6 times since 2017 Last updated: Dec 11, 2015 Started: Aug 31, 2014 Primary completion: Dec 31, 2014 Completion: Mar 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02218346, this PHASE1 trial focuses on Healthy Volunteers and remains completed. Sponsored by Agios Pharmaceuticals, Inc., it has been updated 6 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Aug 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Agios Pharmaceuticals, Inc.
Celgene Corporation

Data source: Agios Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baltimore, United States